Lamivudine

Generic Name
Lamivudine
Brand Names
Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
Drug Type
Small Molecule
Chemical Formula
C8H11N3O3S
CAS Number
134678-17-4
Unique Ingredient Identifier
2T8Q726O95
Background

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication

For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions
Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine

Phase 3
Completed
Conditions
Hepatitis B
Malignancy
Interventions
Drug: Lamivudine
Drug: Entecavir
First Posted Date
2012-04-18
Last Posted Date
2017-06-29
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
180
Registration Number
NCT01580202
Locations
🇰🇷

National Cancer Center, Korea, Goyang, Gyeonggi, Korea, Republic of

🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

and more 2 locations

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

First Posted Date
2012-02-08
Last Posted Date
2016-03-11
Lead Sponsor
University of Michigan Rogel Cancer Center
Registration Number
NCT01528865
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

First Posted Date
2011-12-09
Last Posted Date
2016-04-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
297
Registration Number
NCT01489046
Locations
🇺🇸

Orlando Immunology Center, Orlando, Florida, United States

🇺🇸

Jacobi Medical Center, Bronx, New York, United States

🇹🇭

Local Institution, Nontaburi, Thailand

and more 12 locations

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Phase 2
Completed
Conditions
Hepatitis B Virus
HBV
Interventions
Drug: Entecavir
Drug: Lamivudine
First Posted Date
2011-09-22
Last Posted Date
2012-08-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1053
Registration Number
NCT01438424

Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

Completed
Conditions
Hepatitis B, Chronic
Interventions
Drug: Lamivudine
First Posted Date
2011-06-20
Last Posted Date
2017-05-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
342
Registration Number
NCT01376154

Lamivudine and Adefovir Dipivoxil Fixed Dose Combination

First Posted Date
2011-05-16
Last Posted Date
2017-08-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
40
Registration Number
NCT01353742
Locations
🇭🇰

GSK Investigational Site, Shatin, New Territories, Hong Kong

Study of Options for Second-Line Effective Combination Therapy (SELECT)

First Posted Date
2011-05-12
Last Posted Date
2021-08-05
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
515
Registration Number
NCT01352715
Locations
🇧🇷

Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil

🇲🇼

University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi

🇿🇦

Soweto ACTG CRS (12301), Johannesburg, South Africa

and more 13 locations

Efficacy Optimizing Research of Lamivudine Therapy

First Posted Date
2010-03-16
Last Posted Date
2013-10-30
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
366
Registration Number
NCT01088009
Locations
🇨🇳

First Affiliated Hospital of Guangxi Medical University, NanNing, Guangxi, China

🇨🇳

Xiangya Hospital Central-South Univrsity, ChangSha, Hunan, China

🇨🇳

HangZhou No.6 People Hospital, Hangzhou, Zhejiang, China

and more 21 locations

Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir

First Posted Date
2009-12-02
Last Posted Date
2014-02-10
Lead Sponsor
Asan Medical Center
Target Recruit Count
90
Registration Number
NCT01023217
Locations
🇰🇷

Asan Medical Center, Seoul, the Meteropolis of Seoul, Korea, Republic of

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

Not Applicable
Completed
Conditions
Hepatitis B, Chronic
Interventions
Drug: Lamivudine
Drug: Entecavir
First Posted Date
2009-11-13
Last Posted Date
2015-12-02
Lead Sponsor
The University of Hong Kong
Target Recruit Count
50
Registration Number
NCT01013272
Locations
🇨🇳

The University of Hong Kong, Hong Kong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy